Brokerages Set Biohaven Ltd. (NYSE:BHVN) Price Target at $21.75

Biohaven Ltd. (NYSE:BHVN) has received a consensus rating of “Moderate Buy” from the seventeen analysts that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $21.75.

A number of analysts recently issued reports on the company. Royal Bank Of Canada lifted their price objective on Biohaven from $22.00 to $23.00 and gave the company an “outperform” rating in a research report on Tuesday, August 11th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Biohaven in a research report on Wednesday, May 27th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Biohaven in a research note on Friday, June 26th. Wall Street Zen upgraded Biohaven from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Finally, HC Wainwright reissued a “neutral” rating and issued a $10.00 price target on shares of Biohaven in a research note on Tuesday, May 26th.

Institutional Trading of Biohaven

Several large investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC raised its holdings in shares of Biohaven by 1,145.9% during the 1st quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company’s stock valued at $148,214,000 after purchasing an additional 16,127,247 shares in the last quarter. BlackRock Inc. bought a new stake in Biohaven in the second quarter worth $196,574,000. Suvretta Capital Management LLC boosted its holdings in Biohaven by 83.0% in the fourth quarter. Suvretta Capital Management LLC now owns 10,286,937 shares of the company’s stock worth $116,140,000 after purchasing an additional 4,666,666 shares in the last quarter. Stifel Financial Corp increased its position in Biohaven by 50.3% during the fourth quarter. Stifel Financial Corp now owns 9,939,856 shares of the company’s stock worth $112,221,000 after buying an additional 3,328,506 shares during the last quarter. Finally, Jupiter Topco LLC acquired a new position in Biohaven during the second quarter worth $127,852,000. 88.78% of the stock is owned by institutional investors.

Biohaven Stock Up 3.0%

BHVN stock opened at $13.91 on Wednesday. The company has a 50 day moving average of $14.59 and a two-hundred day moving average of $11.74. The company has a market cap of $2.10 billion, a price-to-earnings ratio of -3.00 and a beta of 1.26. Biohaven has a 12-month low of $7.48 and a 12-month high of $18.57. The company has a quick ratio of 4.73, a current ratio of 4.73 and a debt-to-equity ratio of 21.23.

Biohaven (NYSE:BHVN) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.15). On average, equities analysts anticipate that Biohaven will post -3.11 earnings per share for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.